Physician profile
Nidal Alkurdy
NPI 1548362114
$15,840.49
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,695 · 2020: $321 · 2021: $1,665 · 2022: $414 · 2023: $7,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,160 · Travel and Lodging: $1,335 · Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,160.00 |
| Travel and Lodging | $1,335.48 |
| Food and Beverage | $250.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $7,740.20 | 2020-2023 | Nourianz |
| Lundbeck LLC | $5,535.07 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $1,565.24 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $68.36 | 2019-2022 | |
| Celgene Corporation | $66.65 | 2021-2023 | Zeposia |
| Tanabe Pharma America, INC. | $62.61 | 2019-2023 | |
| Upsher-Smith Laboratories LLC | $60.02 | 2020-2022 | |
| Allergan, INC. | $58.43 | 2019-2022 | |
| Eisai INC. | $50.05 | 2019-2021 | |
| Biogen, INC. | $49.29 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $47.23 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $47.03 | 2019-2022 | |
| Abbvie INC. | $36.00 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $33.01 | 2020-2021 | |
| Boston Scientific Corporation | $32.25 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $30.42 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $30.31 | 2022 | |
| Merz North America, INC. | $28.23 | 2019-2020 | |
| Emd Serono, INC. | $25.46 | 2019-2022 | |
| Livanova USA, INC. | $24.57 | 2020 | |
| Harmony Biosciences LLC | $23.44 | 2020 | |
| Lilly USA, LLC | $22.83 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $17.46 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.38 | 2022 | |
| Corium, LLC | $16.40 | 2022 | |
| Greenwich Biosciences, INC. | $16.27 | 2020 | |
| Philips North America LLC | $15.90 | 2020 | |
| Advanced Respiratory, INC | $15.51 | 2020 | |
| Grifols USA, LLC | $15.40 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.19 | 2019 | |
| Genzyme Corporation | $13.93 | 2020 | |
| Mdd US Operations, LLC | $13.55 | 2020 | |
| Itamar Medical INC | $13.53 | 2022 | |
| Sk Life Science, INC. | $11.85 | 2022 | |
| Acorda Therapeutics, INC | $11.28 | 2020 | |
| Alexion Pharmaceuticals, INC. | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidal Alkurdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.